Cholinergic potentiation of neuroleptic effects in the nucleus accumbens.
The CNS cholinergic agonist spiro-(1-methyl-4-piperidyl)-N-ethyl-succinimide (RS-86) potentiated the ability of typical neuroleptics to inhibit the hyperactivity induced by direct injection of dopamine to the nucleus accumbens of pargyline-pretreated rats. RS-86 did not augment the anti-dopamine actions of clozapine, an atypical neuroleptic. Tricyclic antidepressants alone or in combination with RS-86 had no effect on the hyperactivity. The antidepressants displayed moderate inhibition of dopamine-sensitive adenylate cyclase in homogenates of the limbic system relative to the neuroleptics.
D000109:Acetylcholine / Q000502:physiology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology; D004357:Drug Synergism; D008032:Limbic System / Q000187:drug effects; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects*; D010277:Parasympathomimetics / Q000494:pharmacology*; D010293:Pargyline / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012686:Septal Nuclei / Q000187:drug effects*; D013388:Succinimides / Q000494:pharmacology
D014150:Antipsychotic Agents; D010277:Parasympathomimetics; D013388:Succinimides; C001886:2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione; D010293:Pargyline; D000262:Adenylyl Cyclases; D000109:Acetylcholine; D004298:Dopamine